Trial Profile
A Phase 3, Multicenter, Open Label Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Tazarotene/ulobetasol (Primary) ; Betamethasone-dipropionate/calcipotriol
- Indications Plaque psoriasis
- Focus Adverse reactions; Registrational
- Sponsors Bausch Health Companies; Valeant Pharmaceuticals International
- 12 Oct 2022 Results comparing the efficacy and safety of Cal/BD foam and HP/Taz lotion for up to 52 weeks, published in the Dermatology and Therapy
- 01 Jun 2022 Data from pooled analysis from (NCT02462070; NCT02462122 and NCT02462083) studies published in the Journal of Dermatological Treatment
- 26 Oct 2020 According to a Bausch Health Companies media release, data from this trial will be presented during the virtual Fall Clinical Dermatology Conference 2020.